Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness

被引:25
作者
van Wijk, Yvonka [1 ]
Vanneste, Ben G. L. [1 ]
Walsh, Sean [1 ]
van der Meer, Skadi [1 ]
Ramaekers, Bram [2 ]
van Elmpt, Wouter [1 ]
Pinkawa, Michael [3 ]
Lambin, Philippe [1 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol,MAASTRO,D Lab, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, Maastricht, Netherlands
[3] Univ Hosp RWTH Aachen, Dept Radiat Oncol, Aachen, Germany
关键词
Prostate cancer; Radiotherapy; Implantable rectum spacer; NTCP models; Cost-effectiveness; Decision support; INTENSITY-MODULATED RADIOTHERAPY; MEN; NOMOGRAMS; SURVIVAL; TUMOR; SET; GY;
D O I
10.1016/j.radonc.2017.07.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Previous studies have shown that the implantable rectum spacer (IRS) is not beneficial for all patients. A virtual IRS (V-IRS) was constructed to help identify the patients for whom it is cost-effective to implant an IRS, and its viability as a tool to tailor the decision of an IRS implantation to be beneficial for the specified patient was assessed. Please watch animation: (https://www.youtube.comiwatch?v=tDlagSXMKqw) Materials and methods: The V-IRS was tested on 16 patients: 8 with a rectal balloon implant (RBI) and 8 with a hydrogel spacer. A V-IRS was developed using 7 computed tomography (CT) scans of patients with a RBI. To examine the V-IRS, CT scans before and after the implantation of an IRS were used. IMRT plans were made based on CT scans before the IRS, after IRS and with the V-IRS, prescribing 70 Gray (Gy) to the planning target volume. Toxicity was accessed using externally validated normal tissue complication probability (NTCP) models, and the Cost-effectiveness was analyzed using a published Markov model. Results: The rectum volume receiving 75 Gy (V75) were improved by both the IRS and the V-IRS with on average 4.2% and 4.3% respectively. The largest NTCP reduction resulting from the IRS and the V-IRS was 4.0% and 3.9% respectively. The RBI was cost-effective for 1 out of 8 patients, and the hydrogel was effective for 2 out of 8 patients, and close to effective for a third patient. The classification accuracy of the model, regarding cost-effectiveness, was 100%. Conclusion: The V-IRS approach in combination with a toxicity prediction model and a cost-effectiveness analyses is a promising basis for a decision support tool for the implantation of either a hydrogel spacer or a rectum balloon implant. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 28 条
  • [1] [Anonymous], RADIOTHER ONCOL
  • [2] TABLES OF EQUIVALENT DOSE IN 2 GY FRACTIONS - A SIMPLE APPLICATION OF THE LINEAR-QUADRATIC FORMULA
    BARTON, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (02): : 371 - 378
  • [3] Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness
    Cheng, Qing
    Roelofs, Erik
    Ramaekers, Bram L. T.
    Eekers, Danielle
    van Soest, Johan
    Lustberg, Tim
    Hendriks, Tim
    Hoebers, Frank
    van der Laan, Hans Paul
    Korevaar, Erik W.
    Dekker, Andre
    Langendijk, Johannes A.
    Lambin, Philippe
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 118 (02) : 281 - 285
  • [4] Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy
    De Crevoisier, R
    Tucker, SL
    Dong, L
    Mohan, R
    Cheung, R
    Cox, JD
    Kuban, DA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (04): : 965 - 973
  • [5] A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1
    Fachal, Laura
    Gomez-Caamano, Antonio
    Barnett, Gillian C.
    Peleteiro, Paula
    Carballo, Ana M.
    Calvo-Crespo, Patricia
    Kerns, Sarah L.
    Sanchez-Garcia, Manuel
    Lobato-Busto, Ramon
    Dorling, Leila
    Elliott, Rebecca M.
    Dearnaley, David P.
    Sydes, Matthew R.
    Hall, Emma
    Burnet, Neil G.
    Carracedo, Angel
    Rosenstein, Barry S.
    West, Catharine M. L.
    Dunning, Alison M.
    Vega, Ana
    [J]. NATURE GENETICS, 2014, 46 (08) : 891 - 894
  • [6] Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study
    Gez, Eliahu
    Cytron, Shmuel
    Ben Yosef, Rahamin
    London, Daniel
    Corn, Benjamin W.
    Alani, Shlomi
    Scarzello, Giovanni
    Dal Moro, Fabrizio
    Sotti, Guido
    Zattoni, Filiberto
    Koziol, Ike
    Torre, Taryn
    Bassignani, Matthew
    Kalnicki, Shalom
    Ghavamian, Reza
    Blakaj, Dukagjin
    Anscher, Mitchell
    Sommerauer, Martin
    Jocham, Dieter
    Melchert, Corinna
    Huttenlocher, Stefan
    Kovacs, Gyoergy
    Garg, Madhur
    [J]. RADIATION ONCOLOGY, 2013, 8
  • [7] Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era
    Glass, Allison S.
    Cowan, Janet E.
    Fuldeore, Mahesh J.
    Cooperberg, Matthew R.
    Carroll, Peter R.
    Kenfield, Stacey A.
    Greene, Kirsten L.
    [J]. UROLOGY, 2013, 82 (01) : 60 - 65
  • [8] Hamstra DA, 2016, INT J RAD ONCOL BIOL
  • [9] Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer
    Hoogeman, MS
    van Herk, M
    de Bois, J
    Lebesque, JV
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 74 (02) : 177 - 185
  • [10] Hutchinson R, 2016, UROL ONCOL ELSEVIER, V34, pe19